Applied Therapeutics to Present at the Cowen and Barclays Investor Conferences

Rhea-AI Summary

Applied Therapeutics, Inc. (Nasdaq: APLT) has announced its participation in two key investor conferences in March 2022. The Cowen 42nd Annual Health Care Conference will be held on March 7, 2022, with a panel discussion scheduled from 9:10 to 10:10 a.m. ET. The Barclays Global Healthcare Conference is set for March 17, 2022, featuring a presentation from 10:15 to 10:40 a.m. ET. Interested investors can access the webcast on the company's Investor Relations page and listen to replays afterward. The company focuses on developing treatments for unmet medical needs.

NEW YORK, March 01, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will participate in two upcoming investor conferences in March:

Cowen 42nd Annual Health Care Conference 
Date: Monday, March 7, 2022 
Panel Time: 9:10 – 10:10 a.m. ET

Barclays Global Healthcare Conference 
Date: Thursday, March 17, 2022 
Presentation Time: 10:15 – 10:40 a.m. ET

Webcast information for the Cowen 42nd Annual Health Care Conference Orphan Neuro panel discussion and Barclays Global Healthcare Conference presentation will be accessible on the Events page under the Investor Relations section of the Applied Therapeutics website at www.appliedtherapeutics.com. A replay will also be available following the webcast.

About Applied Therapeutics

Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. Applied Therapeutics’ portfolio includes three Phase 3 programs for diseases with high unmet medical need and no approved treatment options. The Company’s lead drug candidate, AT-007, is a novel central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including Galactosemia and SORD Deficiency. The Company is also developing AT-001, a novel potent ARI, for the treatment of Diabetic Cardiomyopathy, or DbCM, a fatal fibrosis of the heart.

To learn more, please visit www.appliedtherapeutics.com and follow the company on Twitter @Applied_Tx. A copy of the Company’s February 2022 Corporate Presentation is posted to the Investor Relations section of Applied Therapeutics’ website.

Contacts

Investors:
Maeve Conneighton, Eric Kasper
(212) 600-1902 or
appliedtherapeutics@argotpartners.com

Media:
media@appliedtherapeutics.com

FAQ

When will Applied Therapeutics participate in the Cowen 42nd Annual Health Care Conference?

Applied Therapeutics will participate in the Cowen 42nd Annual Health Care Conference on March 7, 2022, from 9:10 to 10:10 a.m. ET.

What is the date and time for Applied Therapeutics' presentation at the Barclays Global Healthcare Conference?

The presentation by Applied Therapeutics at the Barclays Global Healthcare Conference will take place on March 17, 2022, from 10:15 to 10:40 a.m. ET.

Where can I find the webcast information for Applied Therapeutics' investor conferences?

Webcast information for the investor conferences can be found on the Events page in the Investor Relations section of the Applied Therapeutics website.

What is the primary focus of Applied Therapeutics?

Applied Therapeutics focuses on developing novel drug candidates for high unmet medical needs, including treatments for CNS rare metabolic diseases.